Table 3.

Prevalence of HPV in HNSCCs by cancer site and geographic location

No. studiesNo. casesOverall HPV prevalence (95% CI)HPV16 prevalence (95% CI)
Oral cavity
    Europe1574416.0 (13.4-18.8)10.8 (8.6-13.2)
    North America857716.1 (13.2-19.4)10.1 (7.7-12.8)
    Asia131,13333.0 (30.3-35.8)22.3 (20.3-25.2)
    Other*218818.1 (12.9-24.3)14.9 (10.1-20.8)
Oropharynx
    Europe1752928.2 (24.4-32.2)23.8 (20.2-27.7)
    North America728547.0 (41.1-53.0)42.1 (36.3-48.1)
    Asia45446.3 (32.6-60.4)35.2 (22.7-49.4)
    Other*210136.6 (27.3-46.8)33.7 (24.6-43.8)
Larynx
    Europe1979921.3 (18.5-24.3)13.8 (11.5-16.4)
    North America729713.8 (10.1-18.3)10.1 (7.0-14.1)
    Asia830638.2 (32.8-43.9)26.5 (21.6-31.8)
    Other*13348.5 (30.8-66.5)45.5 (28.1-63.6)
  • * Includes Central and South America, Australia, and Africa.

  • Larynx includes cases of the hypopharynx.